---
document_datetime: 2023-09-21 18:09:14
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/thelin-epar-procedural-steps-taken-authorisation_en.pdf
document_name: thelin-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5380698
conversion_datetime: 2025-12-30 01:10:14.309042
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Encysive  (UK)  Limited  submitted  on  28  July  2005  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Thelin,  through  the  centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 25 May 2005.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application The  applicant  Encysive  (UK)  Limited  submitted  on  28  July  2005  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for Thelin,  which  was  designated  as  an  orphan  medicinal  product  EU/3/04/234  on  21  October  2004. Thelin  was  designated  as  an  orphan  medicinal  product  in  the  following  indication:  Treatment  of pulmonary arterial hypertension and chronic thromboembolic pulmonary. The calculated prevalence of this condition was below 2 per 100,000 EU population. The  applicant applied for the following indication 'for the treatment of pulmonary  arterial hypertension  in  patients  with  WHO  Class  II,  III,  or  IV  symptoms  to  improve  exercise  ability, functional status, and decrease the rate of clinical worsening.' Information relating to Orphan Market Exclusivity Similarity Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No  847/2000,  the  application  contained  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products (see Appendix 1). Scientific Advice The applicant did not seek scientific advice or Protocol Assistance at the CHMP. Licensing status: The product was not licensed in any country at the time of submission of the application. The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Dr. J.F.F. Lekkerkerker Co-Rapporteur: Dr. K. Broich EMEA Product Team Leader: A. Zanoletty Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 28 July 2005.
- The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 28 October 2005 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 04 November 2005 (Annex 2).
- The procedure started on 17 August 2005.
- During the meeting on 12 -15 December 2005, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 15 December 2005 (Annex 3).

<!-- image -->

· The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 17 February 2006. · The  summary  report  of  the  inspection  carried  out  at  the  following  site(s)  Aptuit,  Inc.  10245 Hickman Mills Drive, Kansas City, Missouri 64134-0708, between 18-20 April 2006 was issued on 12 May 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 21 April 2006 (Annex 4). · During  the  CHMP  meeting  on  24-27  April  2006,  the  CHMP  agreed  on  a  list  of  outstanding issues to be addressed in writing by the applicant. The final consolidated List of Outstanding issues was sent to the applicant on 27 April 2006.  (Annex 5). · The applicant submitted the responses to the CHMP list of outstanding issues on 10 May 2006. · The Rapporteurs circulated a Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on 19 May 2006 (Annex 6). · During  the  meeting  on  29  May  -1  June  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Thelin on 1 June 2006. The applicant provided the letter of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  30  May  2006 Annex 7. · The  CHMP  adopted  a  report  on  similarity  of  Thelin  with  Tracleer  (bosentan),  Ventavis (iloprost)  on  14  -  17  November,  and  with  Revatio  (sildenafil)  on  the  1  June  2006.  (see Appendix 5.1.) · The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 10 August 2006. Medicinal product no longer authorised